摘要
眼睑基底细胞癌(BCC)是眼睑恶性肿瘤中最常见的类型。手术切除是治疗眼睑BCC的公认金标准,但对于局部晚期或转移性BCC,较大的手术风险和不良预后是困扰医患的最大问题,因此有必要探索新治疗方案。目前靶向治疗具有良好前景,但现有的靶向药物(Hedgehog信号通路抑制剂)面临难以完全清除肿瘤、毒性作用严重以及耐药的发生问题。鉴于以上情况,开发新的靶向药物对治疗该病具有重要意义。Hippo信号通路和Notch信号通路在眼睑BCC的发生和发展中起着重要作用,可能成为治疗的新靶点。因此,本文综述了Hippo信号通路和Notch信号通路在眼睑BCC中的研究进展,旨在为眼睑BCC的靶向治疗提供新的思路。
Eyelid basal cell carcinoma(BCC)is the most common type of eyelid malignancy.Surgical resection is the recognized gold standard in the treatment of eyelid BCC,but for locally advanced or metastatic BCC,greater surgical risk and poor prognosis are the biggest issue that plagues doctors and patients,so it is necessary to explore new treatment options.Currently,targeted therapy has a good prospect,but the existing targeted drugs(Hedgehog signaling pathway inhibitors)face difficulties in completely eliminating tumors,serious toxic reactions and the occurrence of drug resistance.In view of this,the development of new targeted drugs is of great significance for the treatment of this disease.Hippo signaling pathway and Notch signaling pathway play an important role in the occurrence and development of eyelid BCC,and may become a new target for treatment.Therefore,this paper reviews the research progress on Hippo signaling pathway and Notch signaling pathway in eyelid BCC,aiming to provide new ideas for the targeted therapy of eyelid BCC.
作者
于珞涵
刘龙飞
李超鹏
YU Luohan;LIU Longfei;LI Chaopeng(Department of Ophthalmology,the Affiliated Huaian No.1 People's Hospital of Nanjing Medical University,Huaian,Jiangsu 223300,China;Central Laboratory,the Affiliated Huaian No.1 People's Hospital of Nanjing Medical University,Huaian,Jiangsu 223300,China)
出处
《转化医学杂志》
2024年第1期141-146,共6页
Translational Medicine Journal
基金
江苏省医学青年人才项目(QNRC2016430)
淮安市自然科学研究计划(联合专项)卫生健康类科研项目(HABL202231)。
